Wang et al. demonstrated that in osteosarcoma treatment, sorafenib significantly inhibited the increase in PD-L1 expression induced by doxorubicin, thereby promoting the activity and proportion of CD8+ T cells in the TME, further confirming the significance of CD8+ T cells in resisting osteosarcoma (Wang et al., 2023b). Here, CD8A is linked to osteosarcoma.